These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12781432)

  • 1. In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line.
    Kanzawa F; Akiyama Y; Saijo N; Nishio K
    Lung Cancer; 2003 Jun; 40(3):325-32. PubMed ID: 12781432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines.
    Kawamura-Akiyama Y; Kusaba H; Kanzawa F; Tamura T; Saijo N; Nishio K
    Lung Cancer; 2002 Oct; 38(1):43-50. PubMed ID: 12367792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Rogers P; Boxall FE; Allott CP; Stephens TC; Kelland LR
    Eur J Cancer; 2002 Aug; 38(12):1653-60. PubMed ID: 12142057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients.
    Medina-Gundrum L; Cerna C; Gomez LR; Yochmowitz M; Weitman S
    Anticancer Drugs; 2003 Apr; 14(4):275-80. PubMed ID: 12679731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
    Kanzawa F; Koizumi F; Koh Y; Nakamura T; Tatsumi Y; Fukumoto H; Saijo N; Yoshioka T; Nishio K
    Clin Cancer Res; 2001 Jan; 7(1):202-9. PubMed ID: 11205910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
    Plasencia C; Abad A; Martinez-Balibrea E; Taron M
    Invest New Drugs; 2004 Nov; 22(4):399-409. PubMed ID: 15292710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
    Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
    Konecny G; Untch M; Slamon D; Beryt M; Kahlert S; Felber M; Langer E; Lude S; Hepp H; Pegram M
    Breast Cancer Res Treat; 2001 Jun; 67(3):223-33. PubMed ID: 11561768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
    Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
    J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine.
    Flaherty KT; Stevenson JP; Redlinger M; Algazy KM; Giatonio B; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2004 May; 53(5):404-8. PubMed ID: 15129676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines.
    Bahadori HR; Rocha Lima CM; Green MR; Safa AR
    Anticancer Res; 1999; 19(6B):5423-8. PubMed ID: 10697572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
    Voigt W; Kegel T; Weiss M; Mueller T; Simon H; Schmoll HJ
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):585-90. PubMed ID: 16021466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
    Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
    Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
    Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M
    Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental study of combination therapy with S-1 against pancreatic cancer.
    Yoshizawa J; Takizawa A; Takeuchi O; Hiraku O; Sasaki K; Morimoto Y; Atsuda K; Inoue G; Suzuki Y; Asanuma F; Yamada Y
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1211-9. PubMed ID: 19337733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
    Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
    Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development and characterization of a gemcitabine-resistant variant of human lung adenocarcinoma cell line A549].
    Dong M; Lin C; Feng FY; Zhang XY; Fu M; Liang X; Lu HY; Zha YY; Wu M
    Ai Zheng; 2004 Jun; 23(6):667-71. PubMed ID: 15191667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.